IFP Advisors’s Castle Biosciences CSTL Stock Holding History

IFP Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.08K	Buy	143 +83	+138%	+$2.5K	﹤0.01%	3809
2026 Q2	$1.43K	Buy	60 +8	+15%	+$178	﹤0.01%	4382
2026 Q1	$1.28K	Hold	52	–	–	﹤0.01%	4121
2025 Q4	$2.02K	Hold	52	–	–	﹤0.01%	3832
2025 Q3	$1.18K	Buy	52 +16	+44%	+$325	﹤0.01%	3890
2025 Q2	$1.27K	Buy	+36	New	+$666	﹤0.01%	4122
2025 Q1	–	Sell	-161	Closed	-$4.29K	–	4386
2024 Q4	$4.29K	Buy	+161	New	+$4.9K	﹤0.01%	2845
2023 Q3	–	Sell	-11	Closed	-$151	–	3351
2023 Q2	$151	Hold	11	–	–	﹤0.01%	3332
2023 Q1	$235	Hold	11	–	–	﹤0.01%	3261
2022 Q4	$1K	Buy	+11	New	+$255	﹤0.01%	4308

Other funds holding CSTL

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

FBT

First Bank & Trust Brookings, South Dakota $687M AUM 18.35% 1-Year Est. Return

GAA

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

Oak Harvest Investment Services Houston, Texas $1.07B AUM 32.83% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

GWM

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

IFP Advisors's CSTL Position: Q3 2026 in Review

IFP Advisors increased its Castle Biosciences (CSTL) stake by 138% in Q3 2026, buying an estimated $2.5K and bringing the position to 143 shares worth $5.08K. The position accounts for ﹤0.01% of the portfolio, ranked #3809.

IFP Advisors first reported a position in CSTL in Q4 2022 and has held it in 10 quarters since. 14 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.

IFP Advisors held 143 shares of Castle Biosciences worth $5.08K as of Q3 2026.
IFP Advisors bought 83 Castle Biosciences shares in Q3 2026, an estimated $2.5K.
Castle Biosciences made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #3809 holding.
IFP Advisors first reported a position in Castle Biosciences in Q4 2022 and has held it in 10 quarters since.
14 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.